Brilinta tv commercials
TV spots
TV commercials Brilinta
Advertisers
Advertisers of commercials featuring Brilinta
Brilinta
Brilinta is not a company, but rather a medication developed by the pharmaceutical company AstraZeneca. Brilinta, also known by its generic name ticagrelor, is an oral antiplatelet medication used in...
Actors
Actors who starred in Brilinta commercials
Agenices
Agencies worked with Brilinta
Healix
Patients & Purpose
What is Brilinta?
Brilinta (ticagrelor) is a medication used to prevent blood clots in people with acute coronary syndrome (ACS) or a history of heart attack. It belongs to a class of drugs known as antiplatelet agents, which work by preventing platelets in the blood from sticking together and forming clots.
Mechanism of ActionBrilinta acts by inhibiting a specific receptor called P2Y12 on the platelet cell surface. By blocking this receptor, Brilinta prevents the activation and aggregation of platelets, thereby reducing the risk of clot formation in the arteries.
Uses and IndicationsBrilinta is primarily prescribed to people with ACS, including those with unstable angina or myocardial infarction (heart attack), to reduce the risk of future cardiovascular events. It is typically used in combination with aspirin to provide dual antiplatelet therapy.
Efficacy and SafetySeveral clinical studies have demonstrated the efficacy of Brilinta in reducing the risk of cardiovascular events, such as heart attack, stroke, or cardiovascular death, compared to other antiplatelet agents. Brilinta has shown superiority over the commonly used drug, clopidogrel (Plavix), in terms of preventing cardiovascular events in ACS patients.
As with any medication, Brilinta comes with potential side effects. The most common side effects include bleeding, such as nosebleeds, bruising, or gastrointestinal bleeding. It is important for patients taking Brilinta to follow their healthcare provider's instructions and report any significant bleeding or other adverse effects promptly.
Dosage and AdministrationBrilinta is typically initiated with a loading dose of 180 mg, followed by a maintenance dose of 90 mg twice daily. The recommended duration of treatment varies depending on the patient's condition and the healthcare provider's judgment.
It is worth noting that Brilinta may interact with other medications, especially those that affect blood clotting. Therefore, it is essential for patients to inform their healthcare provider about all the medications they are taking to avoid potential drug interactions.
ConclusionBrilinta (ticagrelor) is an antiplatelet medication commonly used in the management of acute coronary syndrome to reduce the risk of further cardiovascular events. It works by inhibiting platelet aggregation, thereby preventing blood clot formation. While Brilinta has demonstrated efficacy in clinical studies, it is important for patients to be aware of potential side effects and to use the medication under the guidance of a healthcare professional.
